207 related articles for article (PubMed ID: 18794619)
1. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
[TBL] [Abstract][Full Text] [Related]
2. Different antidiabetic regimens and the development of renal dysfunction in US Veterans with type 2 diabetes mellitus.
Gosmanova EO; Canada RB; Wan J; Mangold TA; Wall BM
J Investig Med; 2012 Oct; 60(7):1009-14. PubMed ID: 22801248
[TBL] [Abstract][Full Text] [Related]
3. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA; Majumdar SR; Simpson SH; Toth EL
Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
[TBL] [Abstract][Full Text] [Related]
5. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
7. Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
Scherrer JF; Morley JE; Salas J; Floyd JS; Farr SA; Dublin S
Ann Fam Med; 2019 Jul; 17(4):352-362. PubMed ID: 31285213
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
[TBL] [Abstract][Full Text] [Related]
9. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
[TBL] [Abstract][Full Text] [Related]
10. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
[TBL] [Abstract][Full Text] [Related]
11. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.
Yang J; Vallarino C; Bron M; Perez A; Liang H; Joseph G; Yu S
Curr Med Res Opin; 2014 Nov; 30(11):2223-31. PubMed ID: 24983744
[TBL] [Abstract][Full Text] [Related]
12. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
13. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
14. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
15. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of longitudinal medication non-adherence on mortality by race/ethnicity among veterans with diabetes.
Egede LE; Lynch CP; Gebregziabher M; Hunt KJ; Echols C; Gilbert GE; Mauldin PD
J Gen Intern Med; 2013 Feb; 28(2):208-15. PubMed ID: 22948932
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
18. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
19. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
20. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]